|
Industry Calls for More Resources to Expedite Generic Drug Approvals in Europe
Generic drug firms operating in the European Union (EU) should work closely with state agencies to mitigate drug approval delays caused by bureaucratic overload, the European Generic medicines Association (EGA) said at an industry conference in February. This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives